TELL : +91 0 99 08 87 07 06

 Mcmed International ®: Largest Journal Publication in world

International Journal of Advances In Case Reports

Volume 11, Issue 1, 2024
Mcmed International
International Journal of Advances In Case Reports
Issn
XXX-XXXX (Print), 2349 - 8005 (Online)
Frequency
bi-annual
Email
editorijacr@mcmed.us
Journal Home page
http://mcmed.us/about/ijacr
Recommend to
A Friend  | A librarian
Purchase
Purchase Issue
Abstract
Title
THE EFFECT OF AROGYAVARDHINI VATI AND PHALATRIKADI KVATHA IN NON ALCOHOLIC FATTY LIVER DISEASE –CASE STUDIES
Author
Ashok Kumar Panda*, Debajyoti Das, Amit Kumar Dixit, Ramakanta Giri, Jayram Hazra
Email
akpanda_06@yahoo.co.in
keyword
Fatty liver, Katuki, Argyavardhini vati, phalatrikadi kvatha, lipids, Body Mass Index.
Abstract
The prevalence of NAFLD is to be around 9-32% in general Indian population, with a higher incidence amongst overweight/obese and diabetic/ pre diabetic patients. There is no satisfactory patient centered clinical outcomes and evidences for NAFLD although a variety of molecules have been attempted to correct wide spectrum of NAFLD. Most of clinical trials are too short to determine the outcomes. Most of the hepatologists recommended life style modification, restricted calories intake and exercise for NAFLD. More than 50% people of our country relay on Ayurveda for liver diseases. Katuki (Picrorhiza kurroa) is mostly used herb of Ayurveda in liver diseases showed reduced lipid content of liver more significantly than silymarin. High concentration of Katuki (Picrorhiza kurroa) contained in two Ayurveda formulations I.e Argyavardhini vati and phalatrikadi kwatha are selected for the treatment of two cases of NAFLD. Both the drugs administrated to one male and one female patient for a period of 12 weeks. Liver function test, Haemogram, Renal function test and cholesterol profile along with ultrasound of liver were performed D0, after 4 weeks, 8weeks and 12 weeks of these two cases. The medication has no side effect and there was no biochemical and haematological abnormality after 12 weeks of treatment. Elevated liver enzymes with elevated liver echogenicity were normalised after 12 weeks of treatment. Randomised control trial is recommended.
Download Broucher
Back to Top >>>>